Quidel Corporation (formerly Diagnostic HYBRIDS, Inc.) is a manufacturer of diagnostic healthcare solutions serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Quidel’s core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. The company’s research and manufacturing operation in Athens, Ohio is on the leading edge of high quality and innovative cellular and molecular testing that is used in hospitals, physician office labs, and research settings. The products developed and manufactured in Ohio include direct fluorescent antibodies (DFA), Enzyme Linked Immunosorbant Assays in a micro-titer plate format with a focus on bone and complement pathway markets, and molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. In addition, Quidel products meet customer needs for specimen collection, specimen transport, multi-virus cell culture amplification, and sensitive and specific virus detection using FDA-cleared monoclonal antibody kits and reagents.